Vergleich

PHA-767491 HCl Europäischer Partner

ArtNr S2742-5000
Hersteller Selleckchem
CAS-Nr. 942425-68-5
Menge 5 g
Quantity options 10 mg 1 g 10 g 10 mM/1 mL 50 mg 5 g
Kategorie
Typ Inhibitors
Specific against other
Smiles C1CNC(=O)C2=C1NC(=C2)C3=CC=NC=C3.Cl
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias CAY10572,NMS 1116354
Similar products PHA-767491, 845714-00-3
Lieferbar
Manufacturer - Targets
CDK9
Storage Conditions
2 years -80 in solvent
Molecular Weight
213, 24
Administration
Intravenous or oral administration twice a day
Animal Models
Female SCID mice subcutaneously implanted with HL60 cells, male Hsd, athymic nu-nu mice subcutaneously implanted with HCT116 cells, A2780 or Mx-1 cells, and female Sprague-Dawley rats with DMBA-induced mammary carcinomas
Cell lines
HeLa, MCF7, HCT-116, U2OS, A2780, K562, SF-539, SF-268, Ovcar8, SW480, COLO205, HCT-15, Jurkat, PC3, and NHDF
Concentrations
Dissolved in DMSO, final concentrations ca. 20 uM
Dosages
ca.50 mg/kg
Formulation
Dissolved in DMSO, and diluted in saline
IC50
10 nM, 10 nM, 10 nM, 10 nM, 10 nM, 10 nM
In vitro
PHA-767491 displays approximately 20-fold selectivity for Cdk1, Cdk2 and GSK3-beta, 50-fold selectivity for MK2 and Cdk5 and 100-fold selectivity for PLK1 and CHK2. PHA-767491 inhibits cell proliferation in a variety of human cell lines with IC50 of 0.86 uM for SF-268 to 5.87 uM for K562, and significantly induces apoptosis in a p53-independent manner in almost all cell lines in contrast with 5-FU or gemcitabine which only works in a few of cell lines. Unlike current DNA synthesis inhibitors, PHA-767491 treatment at 5 uM blocks the initiation of DNA replication but not replication fork progression, due to specific inhibition of Cdc7 kinase and Mcm2 phosphorylation at the Cdc7-dependent Ser40 site. [1] The up-regulated Mcl-1 levels in ABT-737-resistant OCI-LY1 and SU-DHL-4 cells can be significantly decreased by PHA-767491 treatment at 3 uM possibly due to the inhibition of Cdk9, leading to the restoration of the sensitivity to ABT-737. [2] The direct mitochondrial dependent pro-apoptosis effect of PHA-767491 is also observed when applied at 1 uM in quiescent chronic lymphocytic leukemia (CLL) cells through the similar mechanism with EC50 of 0.34-0.97 uM. While in proliferating CLL cells stimulated by CD154 and interleukin-4, PHA-767491 treatment at 5 uM abolishes DNA synthesis by inhibiting Cdc7 rather than triggering cell death. [3]
In vivo
Administration of PHA-767491 twice a day for 5 days significantly inhibits the growth of HL60 xenograft in a dose-dependent manner with TGI of 50% and 92% at dose of 20 mg/kg and 30 mg/kg, respectively, the effect of which is also marked in A2780, Mx-1, and HCT-116 xenograft models as well as the DMBA-induced mammary carcinomas, and correlates with Cdc7 inhibition and subsequently decreased phosphorylation of Mcm2 at the Cdc7-dependent site Ser40 [1]
Incubation Time
24 or 72 hours
Kinase Assay
In vitro kinase assays, The inhibition of Cdc7 and Cdk9 by PHA-767491 (IC50) is determined using the strong anion exchanger (Dowex 1-X8 resin, formate form)-based assay. For each enzyme, the absolute Km values for ATP and the specific substrate are initially determined, and each assay is then run at optimized ATP/33P-gamma-ATP mix (2Km) and substrate (5Km) concentrations. Cdc7 kinase assay is performed in a buffer containing 50 mM Hepes pH 7.9, 15 mM MgCl2, 2 mM beta- glycerylphosphate, 0.2 mg/mL BSA, 1 mM DTT, 3 uM Na3VO4, 2Km ATP/33P-gamma-ATP mix, 5Km Mcm2 (aa 10-294), 37 nM of recombinant Cdc7/Dbf4 and increasing concentration of PHA-767491 in a final volume of 30 uL, and incubated for 1 hour at 25 C. Cdk9 kinase assay is performed using 50 nM of recombinant Cdk9/cyclin T in 50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT, 3 uM Na3VO4, 2Km ATP/33P-gamma-ATP mix, 5Km RNA polymerase CDT peptide and increasing concentration of PHA-767491 in a final volume of 30 uL, and incubated for 1 hour at 25 C. After incubation, an amount of 150 uL of resin/formate (pH 3.0) is added to stop the reaction and capture unreacted 33P-gamma-ATP, separating it from the phosphorylated substrate in solution. After 1 hour of rest, a volume of 50 uL supernatant is transferred to Optiplate 96-well plates. After the additon of 150 uL of Microscint 40, the radioactivity is counted in the TopCount.
Method
Cells are exposed to PHA-767491 for 24 or 72 hours. Cells are lysed and the ATP content in the well, used as a measure of viable cells, is determined using a thermostable firefly luciferase–based assay. Activation of caspase-3 and caspase-7 is measured as a ratio between treated sample and untreated control with a luciferase-based assay, containing a specific proluminescent substrate. DNA replication is measured as incorporation of nucleotide analog BrdU into DNA by flow cytometry.
Solubility (25C)
DMSO 24 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Information
PHA-767491 (CAY10572, NMS 1116354) HCl is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM in cell-free assays, respectively.It displays ~20-fold selectivity against CDK1/2 and GSK3-β, 50-fold selectivity against MK2 and CDK5, 100-fold selectivity against PLK1 and CHK2.
Chemical Name
2-(pyridin-4-yl)-6, 7-dihydro-1H-pyrrolo[3, 2-c]pyridin-4(5H)-one
Features
PHA-767491 is the first inhibitor that directly affects the mechanisms controlling initiation as opposed to elongation in DNA replication.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 5 g
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?